REGENERON PHARMACEUTICALS ($REGN) Releases Q1 2026 Earnings

REGENERON PHARMACEUTICALS (REGN) reported strong Q1 2026 earnings, exceeding both EPS and revenue estimates. The company saw significant insider selling activity, while institutional investors showed mixed sentiment with both large additions and reductions in holdings. Congressional members, however, made purchases of REGN stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin